Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Debiopharm nets funding for antibiotic program
June 2019
SHARING OPTIONS:

LAUSANNE, Switzerland—In mid-May, Debiopharm received $2.1 million in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to support the advancement of Debio 1454, an antibiotic program targeting the multidrug-resistant superbug Acinetobacter baumannii. Debiopharm will receive a total of up to $2.1 million in non-dilutive funding, with the potential for an additional $1.6 million if predetermined milestones are met. Debiopharm will focus on developing an IV antibiotic.
 
“CARB-X’s grant will help support the development of Debio 1454, a new class of antibiotics targeting A. baumannii, one of the priority 1 critical pathogens identified by the WHO. We are really excited to continue developing innovative antibiotics that not only target specific priority pathogens, but also spare the natural microbiome, reducing the potential for dysbiosis and development of resistance,” noted Gregoire Vuagniaux, director of Translational Science, Debiopharm International SA.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.